Sagimet Biosciences $SGMT

Health Care · NASDAQ

$9.08
-0.54 (-5.61%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 1, 2026, the first target we tracked for SGMT.

Sagimet Biosciences (SGMT) is trading down at $9.08 (-5.61%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: July 14, 2023 · $16.00 offering · NASDAQ

Analyst price targets on SGMT

Current price targets from 2 firms average $17, ranging from $7 to $27 — 87% above the current $9.08. Each is tracked to its date and scored the same way a member's call is.

2 targets, newest first. Open a row for its source and scoring.

DateNov 13, 2026 FirmGoldman Sachs RatingSell · reiterates Targetat $10.2 · $7 -32% Horizonby Nov 2027 StatusOpen

Entry price $10.2, the close nearest Nov 13, 2026, when the target was reported; the target is -32% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 13, 2027.

Source Goldman Sachs reiterates Sagimet Biosciences stock Sell rating Investing.com · Nov 13, 2026 · opens the publisher's site
Goldman Sachs reiterated a Sell rating and $7.00 price target on Sagimet Biosciences Inc.
DateOct 1, 2026 FirmCitizens JMP RatingMarket Outperform · lowers Targetat $9.37 · $27 +188% Horizonby Oct 2027 StatusOpen

Entry price $9.37, the close nearest Oct 1, 2026, when the target was reported; the target is +188% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 1, 2027.

Source Citizens cuts Sagimet Biosciences stock price target on trial data Investing.com · Oct 1, 2026 · opens the publisher's site
Citizens lowered its price target on Sagimet Biosciences Inc (NASDAQ:SGMT) to $27.00 from $29.00 while maintaining a Market Outperform rating.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Sagimet Biosciences revenue & net income history (FY2022–FY2025)

RevenueNet incomeNet margin (right axis, %)
$2.00M−$24.5M−$51.0MFY2022 net income: −$30.5M'22FY2023 revenue: $2.00MFY2023 net income: −$27.9M · Net margin −1393.8%'23FY2024 net income: −$45.6M'24FY2025 net income: −$51.0M'25−100%−75%−50%−25%0%FY2023 net margin: −1393.8% (off the scale, which stops at −100.0%)
Sagimet Biosciences annual financial statements
FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue—$2.00M——
Operating income−$31.1M−$30.7M−$54.5M−$56.9M
Operating margin—−1537.0%——
Net income−$30.5M−$27.9M−$45.6M−$51.0M
Net margin—−1393.8%——
EPS (diluted)−$165.20−$2.66−$1.45−$1.58
Balance sheet
Cash and equivalents$158.0K$75.1M$75.8M$35.0M
Total assets$33.0M$96.7M$160.3M$116.5M
Total liabilities$5.36M$5.65M$4.45M$5.10M
Shareholders' equity−$186.9M$91.1M$155.8M$111.4M
Cash flow
Operating cash flow−$24.5M−$23.8M−$42.4M−$45.6M

From Sagimet Biosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Sagimet Biosciences in the news

Nov 13, 2026 Investing.com Goldman Sachs reiterates Sagimet Biosciences stock Sell rating Target
Nov 12, 2026 GlobeNewswire Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Nov 9, 2026 Investing.com Sagimet Biosciences at guggenheim healthcare conference: acne pivot gains traction
Oct 1, 2026 Investing.com Citizens cuts Sagimet Biosciences stock price target on trial data Target

About Sagimet Biosciences

Headquarters
Foster City, California From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →